SNYSanofi

Nasdaq sanofi.com


$ 49.24 $ 0.22 (0.45 %)    

Monday, 03-Jun-2024 15:59:55 EDT
QQQ $ 454.82 $ 2.42 (0.54 %)
DIA $ 398.57 $ -1.29 (-0.33 %)
SPY $ 530.36 $ 0.43 (0.08 %)
TLT $ 91.26 $ 1.15 (1.27 %)
GLD $ 225.37 $ 1.92 (0.89 %)
$ 49.25
$ 48.53
$ 49.23 x 400
$ 49.25 x 200
$ 48.51 - $ 49.40
$ 40.90 - $ 53.45
1,976,104
na
61.88B
$ 0.61
$ 10.36
TBD
na
na ($ 0.08)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 zantac-heart-burn-continues-for-gsk-as-us-court-ruling-allows-thousands-of-zantac-lawsuits-to-move-forward

GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (rani...

 dhl-supply-chain-expands-pharma-logistics-operations-in-france---dhl-group

https://group.dhl.com/en/media-relations/press-releases/2024/dhl-supply-chain-expands-pharma-logistics-operations-in-france.html

 fda-extends-review-deadline-for-regeneronsanofis-dupixent-for-smokers-lungs-disease

The FDA extends the target action date for reviewing Dupixent as an add-on treatment for uncontrolled COPD to September 27, 202...

Core News & Articles

Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for adults with uncontrolled COP...

Core News & Articles

The US Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the sup...

 veecon-2024-speakers-announced-x-ceo-linda-yaccarino-content-creator-khaby-lame-gary-vee-among-special-guests-to-appear-at-festival-that-combines-business-pop-culture-web3

For the third straight year, serial entrepreneur and VeeFriends founder Gary Vaynerchuk (aka Gary Vee) will host an annual conf...

 reported-monday-sanofis-sarclisa-accepted-for-fda-priority-review-for-treating-transplant-ineligible-newly-diagnosed-multiple-myeloma

Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Pr...

 zantac-verdict-jury-finds-no-link-to-colon-cancer-in-initial-trial-gsk-and-boehringer-prevail-in-first-zantac-cancer-lawsuit

Chicago jury rejects woman's claim that Zantac caused her colon cancer. First of thousands of similar lawsuits, companies d...

 first-advanced-oral-treatment-for-asthma---sanofis-investigational-drug-shows-potential

Sanofi reveals Phase 2 results for rilzabrutinib in moderate-to-severe asthma. High and low doses showed a reduction in asthma ...

 hawaii-court-rules-against-bristol-myers-sanofi-in-blood-clot-drug-case-increases-liability-to-916m

A Hawaii judge has ordered Bristol Myers Squibb and Sanofi to pay $916 million for not warning non-white patients about the hea...

 sanofi-new-results-from-rilzabrutinib-phase-2-study-show-potential-to-be-first-advanced-oral-treatment-for-moderate-to-severe-asthma-data-shows-rilzabrutinib-led-to-numerical-reduction-in-loss-of-asthma-control-events-improvement-in-symptoms-and-was-well-tolerated-with-no-new-safety-signals-observed-results-support-the-further-development-and-advancement-into-a-phase-3-program

- Reuters

 chatgpt-parent-open-ai-partners-with-sanofi-formation-bio-to-boost-ai-driven-drug-development

Sanofi collaborates with OpenAI and Formation Bio to enhance drug development. The partnership leverages proprietary data, adva...

 sanofi-formation-bio-and-openai-collaborate-to-develop-ai-powered-software-accelerating-drug-development-and-enhancing-patient-access-to-new-medicines

Sanofi will leverage this partnership to provide access to proprietary data to develop AI models as it continues on its path to...

Core News & Articles

NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% ...

 pfizer-astrazeneca-sanofi-and-mainz-biomed-to-uplevel-europes-pharma-game

On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will...

 takedas-dengue-vaccine-gets-who-approval-eligible-for-un-procurement

Takeda's dengue vaccine, Qdenga, gains WHO prequalification, enabling UN agency procurement. Approved in multiple countries...

 healthcare-giants-pfizer-astrazeneca-sanofi-inject-over-2b-to-boost-frances-healthcare-sector

Pfizer and AstraZeneca invest over $1 billion in France's healthcare sector, bolstering R&D capabilities and job creation.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION